Continuous Chemotherapy Improves Outcomes and Quality of Life in Advanced Breast Cancer
Continuous chemotherapy shows greater benefit in patients with advanced breast cancer
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Continuous chemotherapy shows greater benefit in patients with advanced breast cancer
Innovative breast cancer treatment will be discussed during the first ESMO Breast Cancer Congress in Berlin
Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress 2019.
Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)
Shortages of essential cancer medicines have a direct impact on patient care across Europe.
The newly established 2019 ESMO Breast Cancer Award will be delivered in connection with the inaugural ESMO Breast Cancer Congress
Participants from across the world will meet in Geneva to learn about and discuss the latest research in the field of lung cancer.
A new method of determining the sequence of molecules in DNA can be used to detect small fragments of cancerous genetic material in blood samples from lung cancer patients with a high degree of accuracy.
Françoise Mornex is first female recipient of Heine H. Hansen Award
The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumour types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2019
The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the TAT (Targeted Anticancer Therapies) International Congress 2019
The TAT 2019 Honorary Award for cancer drug development has been given to Dr Geoffrey Shapiro for his leadership in developmental therapeutics, particularly in solid tumours
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.